Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04713982 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

StatusActive, Not Recruiting
PhasePhase 2/3
Started2021-11-19
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 30, 2026 → Jun 30, 2027
See other at-risk trials from Vanderbilt University Medical Center

Amendment history

2026-08-03
Study Status v13
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2026-10-01 → 2027-10-01
2026-04-13
Study Status v12
Primary completion pushed: 2026-03 → 2026-06-30
2026-01-18
Enrolling by Invitation→Active, Not Recruiting Study Status, Oversight v11
Trial statusEnrolling by Invitation→Active, Not Recruiting
Primary completion date2025-12→2026-03
Completion date2026-04-01→2026-10-01
2025-10-22
Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v10
Trial statusRecruiting→Enrolling by Invitation
Primary completion date2025-08→2025-12
Study sitesdetails revised at 1 of 1 site
2025-02-11
Study Status, Contacts/Locations v9
Study sitescontacts updated at 1 of 1 site
Show 8 earlier versions
2024-11-05
Study Status, Oversight, Contacts/Locations v8
Primary completion date2024-08-30→2025-08
Completion date2025-04-01→2026-04-01
Study sitescontacts updated at 1 of 1 site
2023-12-12
Study Status v7
Primary completion date2023-08-30→2024-08-30
Completion date2024-04-01→2025-04-01
2022-12-30
Study Status v6
Primary completion date2023-07-30→2023-08-30
2021-12-26
Study Status v5
Start dateestimated 2021-11-30→confirmed 2021-11-19
2021-11-12
Study Status, Outcome Measures v4
Primary completion date2023-06-30→2023-07-30
Completion date2024-02-01→2024-04-01
Start date2021-07-30→2021-11-30
Secondary endpoints5 to 4 entries
Unified Huntington's Disease Rating Scale (UHDRS) Chorea Scale
2021-06-02
Study Status v3
Primary completion date2022-08-31→2023-06-30
Completion date2023-02-01→2024-02-01
Start date2021-03-26→2021-07-30
2021-03-09
Study Status v2
Start date2021-02-15→2021-03-26
2021-02-02
Study Status, Sponsor/Collaborators v1
Start date2021-01-10→2021-02-15
2021-01-13
Original filing
Examine the effects of deutetrabenazine on functional speech and gait impairment
Trial Details
NCT Number NCT04713982
Lead Sponsor Vanderbilt University Medical Center
Collaborators: Teva Branded Pharmaceutical Products R&D, Inc.
Conditions Huntington Disease
Enrollment 30 participants
Start Date 2021-11-19
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05